Making CAR-T cells in vivo with mRNA

While these strides in CAR-T therapies are exciting for solid tumors (see MD Anderson article – What’s new in CAR-T cell therapy) - leveraging mRNA platform to create in-vivo CAR-T will be truly disruptive. Check this out?https://lnkd.in/eNBDznWD?- wherein researchers at UPenn induced in-vivo creation of CAR-T using mRNA encapsulated in LNP (Lipid NanoParticles). This approach could address in-vitro manufacturing challenges faced by CAR-T, potentially even address CRS and ICANs issues. If the mRNA is based on mapping of neo-antigens expressed by cancer cells this approach might also address potential immune editing by tumor cells. Exciting times ahead across many therapeutic areas!